Treatment of Active CLL with Unmutated IGHV Status in Medically Fit Patients Without TP53 Mutation

Clinical Scenario

This protocol applies to a medically fit patient with active chronic lymphocytic leukemia (CLL) whose disease is characterised by unmutated IGHV status, with no TP53 mutation and no deletion 17p. This molecular profile is a key driver of treatment selection at first-line.

Treatment Approach

For this patient profile, evidence supports a targeted therapy as the primary strategy. Chemoimmunotherapy carries a noted survival disadvantage in this molecular context and is not the preferred option.

The complete regimen, alternatives, sequencing, and decision criteria are in the full structured protocol.